JPMorgan Nasdaq Equity Premium Income ETF vs DENTSPLY SIRONA Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.67, while DENTSPLY SIRONA Inc trades at $13.67 (market cap $2.70B). The key difference: DENTSPLY SIRONA Inc pays a 5.04% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, DENTSPLY SIRONA Inc nearer its low. Which is the better fit depends on your goals.
| JEPQ | XRAY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $16.85 |
52-Week Low | $53.77 | $9.64 |
Market Cap | — | $2.70B |
Enterprise Value | — | $4.84B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $58.59, up 0.14% with a bearish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with covered-call strategies, generating monthly income through dividends. Recent distributions include $0.64, $0.56, and $0.59 per share, highlighting its income-oriented approach. Technical indicators show neutral oscillators but overall bearish momentum with key support at $57.
The outlook remains cautious due to technical bearishness and capped upside from covered calls. Investment appeal centers on high distribution yields for income-focused investors, though performance may lag pure Nasdaq-100 ETFs during rallies. Risks include strategy underperformance in bull markets and dependency on options income sustainability.
DENTSPLY SIRONA (XRAY) trades at $13.57, down 3.48% with bearish technical indicators despite a bullish moving average signal. The company shows persistent challenges with negative net income margins (-17.06%) and declining revenue trends from $3.9B in 2022 to $3.7B in 2025. Recent Q1 2026 earnings missed estimates ($0.27 vs. $0.28 expected), continuing a pattern of underperformance. Analyst sentiment remains cautious with a 'Hold' consensus rating and $13.33 price target, slightly below current levels.
The stock faces significant fundamental headwinds including consecutive earnings misses, declining profitability, and rising debt-to-asset ratio (42.88% in 2025). While technical indicators show some bullish momentum, the weak financial performance and negative investor sentiment suggest limited near-term upside potential. The appointment of a new CFO and distribution expansions provide some operational optimism, but execution risks remain elevated.
Trailing returns across standard periods
Latest headlines on both assets
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →